Time to first subsequent therapy (TFST) defined as the time from initiation of olaparib therapy (index date) to the start of the first subsequent therapy or death, whichever is earlier. For any patient not known to have died and who has not started a subsequent treatment to olaparib at the end of follow-up, TFST will be right-censored at the last recorded day of follow up.

Real-world Progression-free survival 2 (rwPFS2) defined as the time from initiation of olaparib therapy (index date) until earliest record of second disease progression determined by physician's assessment, or death. For any patient without second disease progression, and not known to have died at end of follow-up, rwPFS2 will be right-censored at the date of last follow up.

Time to second subsequent therapy (TSST) defined as the time from initiation of olaparib therapy (index date) to the start of the second subsequent therapy or death, whichever is earlier. For any patient not known to have died and who have not started a second subsequent treatment to olaparib at the end of follow-up, TSST will be right-censored at the last recorded day of follow-up

Symptomatic skeletal related events free-survival (SSEFS) defined as the time from initiation of olaparib therapy (index date) until earliest record of symptomatic skeletal related events, or death. For any patient without symptomatic skeletal-related events not known to have died at the end of follow-up, SSEFS will be right-censored at the date of last follow-up.

Specialty, type of institution (public/private), region

Ethnicity

Weight

Disease stage at tumor diagnosis

Stage of tumor

Localization of metastases

Imaging modality

Time between all cancer stages (PC, mPC, mCRPC),

Gleason score

PSA level

Risk Criteria

o Systemic treatment, surgical intervention, radiotherapy, response to treatment,

o Previous, at baseline and subsequent treatment modalities

Standard assessment

o Clinical outcomes: as defined above

o Timing of BRCA testing

o Rate and reasons for olaparib dosage changes, dose interruptions, treatment cessation, or death

ECOG performance status

Age

Medical history and comorbidities of interest

G8 score

Body mass index

Height